iRhythm Technologies announces Karen Ling to its Board of Directors

– USA, CA –  iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of Karen Ling, an experienced HR leader, to its Board of Directors effective November 1, 2021.

“On behalf of the entire iRhythm team, I am pleased to welcome Karen to our Board of Directors,” commented CEO, Quentin Blackford. “Karen is a renowned HR leader in the healthcare and insurance industries and brings a wealth of experience and unique perspectives to iRhythm. Karen will play an important role in guiding iRhythm’s organizational goals and strategies as the business continues to scale on a global basis. We are looking forward to Karen’s contributions.”

The company also announced the retirement of Raymond Scott from the Board, effective November 1, 2021.

About Karen Ling

Ms. Ling recently retired from her role as EVP and CHRO for American International Group, Inc., a position she had held since July 2019. In this role, Ms. Ling oversaw all aspects of human capital management, including talent acquisition, training, development, compensation and benefits, and diversity, equity, and inclusion. From 2014 until joining AIG, Ms. Ling served as EVP and CHRO at Allergan plc., a pharmaceutical company. In this capacity, Ms. Ling developed and oversaw a global HR strategy during a period of transition that included successfully launching new company-wide HR and cultural initiatives. Previously Ms. Ling was SVP, Human Resources for Merck & Co., Inc.’s Global Human Health and Consumer Care businesses worldwide. Before Merck, she was Group VP, Global Compensation & Benefits at Schering-Plough. Ms. Ling also spent 14 years at Wyeth in various positions of increasing responsibility developing HR strategies for business units and working in Wyeth’s Labor & Employment Department. Before Wyeth, Ms. Ling practiced law in Boston, Massachusetts.

“I am honored to join the iRhythm Board,” said Ms. Ling. “iRhythm is a special company that has proven its ability to innovate and deliver a highly valuable technology and service to patients and providers. I am looking forward to contributing my expertise and counsel as iRhythm continues to scale its operations and expand its market opportunities.”

Ms. Ling holds a J.D. from Boston University School of Law and a B.A. in Economics from Yale University.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team